CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma

Inclusion Criteria: * all risk groups in international prognostic index * diagnosis of aggressive T-cell-lymphoma, confirmed by an excisional biopsy of a lymph node or by sufficiently extensive biopsy of an extranodal involvment, if there is no lymph node involvment. * these lymphomas comprise: peripheral T-cell lymphoma PTCL-NOS Lennert´s lymphoma T-zone lymphoma angioimmunoblastic T-cell-lymphoma * Performance status: ECOG (Eastern Cooperative Oncology Group Score) 0-3(Karnofsky index 40-100%) * written consent of the patient * Declaration of center participation Exclusion Criteria: * Already initiated lymphoma therapy(exept for the prephase treatment specified for this study) * Serious accompanying disorder or impaired organ function * bone marrow involvement\>25% * Known hypersensitivity to medications to be used * Know HIV-positivity * Active hepatitis infection, active CMV infection, prior florid tuberculosis * floride systemic infections * suspicion that patient compliance will be poor * Simultaneous participation in any the study protocol * prior chemo-or radiotherapy for malignancy * other concomitant malignant disease * Pregnancy or lactation period